PharmaGap and MD Biosciences Announce a Collaboration to Pursue Development of a Novel PKC Theta Inhibitor
PharmaGap Inc. and MD Biosciences GmbH have entered into a co-development collaboration pertaining to novel compounds for therapeutic usage in inflammatory and neurological applications, including potentially arthritis and multiple sclerosis. MD Biosciences has been granted exclusive access to a series of novel peptide compounds designed by PharmaGap as inhibitors of protein kinase c theta ("PKC theta").
PKC theta is a cellular signaling molecule associated with processes believed to contribute to many inflammatory and neurological disease conditions. MD Biosciences will assess the PharmaGap compounds in order to characterize their activity against PKC theta and then identify specific disease conditions in the areas of inflammation and neurology where the compounds may prove to be of therapeutic value. MD Biosciences would act as the lead partner to then commercialize the compounds for these specific therapeutic indications. Commercialization rights on generated intellectual property will be shared by the companies. Details of the agreement remain confidential.
Other news from the department business & finance
